With over 35 years of clinical research experience, Peter brings medical, scientific, and business insights into oncology and hematology drug development. His understanding of the clinical development – ranging from feasibility assessments, medical monitoring oversight, regulatory strategy, and patient safety provide him with insights for our conversation on how emerging immunotherapy combinations and novel approaches are influencing global clinical research.
Peter holds an MD and PhD from Ludwig-Maximilians-Universität München.